This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The first randomized trial to investigate preventive ablation of a potential arrhythmogenic substrate associated with coronary chronic total occlusion (CTO) in patients at high risk of ventricular arrhythmias (VAs) reduces the risk of appropriate implantable cardioverter-defibrillator (ICD) therapy and unplanned hospitalization in patients with no (..)
They include medications that are not very effective and cause unpleasant side effects, an implantable cardioverter-defibrillator (or ICD) that provides an internal shock to correct the heartbeat, and a procedure called catheter ablation. Unfortunately, ablation also destroys healthy heart tissue in the process.
The most common arrhythmia, atrial fibrillation , will affect approximately 12.1 Pacemakers and implantable cardioverter defibrillators (ICDs) are the standard of care to regulate a patient’s irregular heartbeat. million people in the United States by 2030, based on an estimation from the Centers for Disease Control and Prevention.
Ventricular tachycardia is a potentially life threatening cardiac arrhythmia. Chronic recurrent monomorphic VT like fascicular tachycardia and right ventricular outflow tract tachycardia are also amenable to electrophysiological mapping and ablation. If the rate is very fast, hemodynamic deterioration can occur rapidly.
Brugada syndrome (BrS) is a genetic heart disease that predisposes individuals to ventricular arrhythmias and sudden cardiac death. Although implantable cardioverter-defibrillators (ICDs) and quinidine are primary treatments, recurrent BrS-triggered ventricular arrhythmias can persist.
However, he suddenly developed a series of malignant ventricular arrhythmias. He required multiple defibrillations within a period of a few hours. Below are printouts of some of the arrhythmias recorded. This time, the arrhythmia did not spontaneously terminate — but rather degenerated to VFib, requiring defibrillation.
Recent advancements in catheter ablation for structural ventricular tachycardia (VT), such as high-density mapping and cardiac imaging-based detection of target areas, have significantly improved the efficacy of ablation procedures.
Ablation will be performed with the use of a substrate-based approach in which the myocardial scar is mapped and ablated while the heart remains predominantly in sinus rhythm. Cardiovascular mortality, driven by sudden cardiac death, is the main reason for dying while waiting for heart transplantation (HTx).
In the PARTITA trial antitachycardia pacing (ATP) predicted the occurrence of implantable cardioverter-defibrillator (ICD) shocks. Catheter ablation of ventricular tachycardia after the first shock reduced the risk of death or worsening heart failure (wHF).
Sudden cardiac death remains the main killer of adults in industrialized countries and reentrant ventricular arrhythmia (VA) is its main underlying mechanism1.
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a disease characterised by fibrofatty replacement of the ventricular myocardium due to specific mutations, leading to ventricular arrhythmias and sudden cardiac death. Emerging evidence suggests that combining flecainide and bisoprolol may be efficacious.
The possibility of an ischemic cause of the ventricular arrhythmia has to be considered! A workup was undertaken in search of a cause of the patient's ventricular arrhythmia. Once the arrhythmia was under control cardiac MRi was performed. The patient has been scheduled for a PVC ablation procedure. No PVCs are seen.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
74 
Let's personalize your content